公开(公告)号：US11052131B2

公开(公告)日：2021-07-06

申请号：US16339931

申请日：2017-10-04

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  UNIVERSITE DE BORDEAUX ,  INSTITUT BERGONIÉ

发明人： Géraldine Siegfried ,  Abdel-Majid Khatib ,  Jean-Luc Hoepffner ,  Serge Evrard

IPC分类号： A61K38/22 ,  A61P35/00 ,  C07K14/575

摘要： Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.

公开(公告)号：US09593153B2

公开(公告)日：2017-03-14

申请号：US14391404

申请日：2013-04-09

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE PARIS-SUD XI ,  UNIVERSITE DE BORDEAUX

发明人： Geraldine Siegfried ,  Abdel-Majid Khatib

IPC分类号： A61K38/18 ,  C07K14/475 ,  C12N5/10 ,  C12N1/21 ,  C12N15/63 ,  C07K14/575 ,  C07K14/47

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K14/47

摘要： The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.

摘要翻译： 本发明涉及多肽及其作为apelin抑制剂的用途。 更具体地说，本发明涉及包含如SEQ ID NO：1所示的序列的多肽，其中至少一个第18,19,22或23位的精氨酸残基被取代或缺失。